Acorn Financial Advisory Services Inc. ADV Boosts Stock Position in DexCom, Inc. (NASDAQ:DXCM)

Acorn Financial Advisory Services Inc. ADV increased its holdings in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 42.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 20,565 shares of the medical device company's stock after purchasing an additional 6,166 shares during the quarter. Acorn Financial Advisory Services Inc. ADV's holdings in DexCom were worth $1,599,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in DXCM. Versant Capital Management Inc purchased a new position in shares of DexCom in the fourth quarter worth about $25,000. Private Trust Co. NA lifted its position in DexCom by 266.3% in the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock valued at $26,000 after purchasing an additional 245 shares during the last quarter. Optiver Holding B.V. purchased a new stake in shares of DexCom during the fourth quarter valued at approximately $33,000. TD Private Client Wealth LLC grew its holdings in shares of DexCom by 62.8% in the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock worth $34,000 after purchasing an additional 167 shares during the last quarter. Finally, Larson Financial Group LLC increased its stake in shares of DexCom by 40.5% in the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock worth $37,000 after buying an additional 137 shares during the period. 97.75% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

DXCM has been the topic of a number of recent analyst reports. Redburn Atlantic upgraded DexCom from a "neutral" rating to a "buy" rating and lifted their price objective for the stock from $85.00 to $115.00 in a research report on Monday, February 3rd. Mizuho started coverage on shares of DexCom in a report on Thursday, April 10th. They issued an "outperform" rating and a $85.00 price target on the stock. Canaccord Genuity Group upped their price objective on shares of DexCom from $103.00 to $106.00 and gave the stock a "buy" rating in a report on Friday. Citigroup lifted their target price on shares of DexCom from $101.00 to $104.00 and gave the company a "buy" rating in a research note on Tuesday, March 4th. Finally, Baird R W raised shares of DexCom from a "hold" rating to a "strong-buy" rating in a research note on Thursday, January 16th. Five analysts have rated the stock with a hold rating, thirteen have issued a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat, DexCom presently has an average rating of "Moderate Buy" and a consensus target price of $99.22.

DexCom Stock Up 16.2 %

NASDAQ DXCM traded up $11.36 during mid-day trading on Friday, reaching $81.62. The stock had a trading volume of 10,694,799 shares, compared to its average volume of 4,266,404. The company has a fifty day moving average price of $71.46 and a 200 day moving average price of $76.87. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. DexCom, Inc. has a 1 year low of $57.52 and a 1 year high of $132.26. The stock has a market cap of $32.00 billion, a PE ratio of 57.08, a price-to-earnings-growth ratio of 2.30 and a beta of 1.50.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.01). The business had revenue of $1.04 billion during the quarter, compared to the consensus estimate of $1.02 billion. DexCom had a return on equity of 30.14% and a net margin of 14.29%. DexCom's quarterly revenue was up 12.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.32 earnings per share. On average, research analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current year.

Insider Activity

In other news, EVP Jereme M. Sylvain sold 7,000 shares of the stock in a transaction on Monday, March 10th. The shares were sold at an average price of $73.83, for a total value of $516,810.00. Following the completion of the sale, the executive vice president now directly owns 135,482 shares of the company's stock, valued at $10,002,636.06. This represents a 4.91 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Kevin R. Sayer sold 32,498 shares of the company's stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total transaction of $2,287,209.24. Following the completion of the transaction, the chief executive officer now directly owns 372,029 shares of the company's stock, valued at $26,183,401.02. This represents a 8.03 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 66,926 shares of company stock valued at $4,734,384 in the last ninety days. Corporate insiders own 0.32% of the company's stock.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.